Clinical study for the treatment of Rosacea with different concentrations of Botulinum Toxin A

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027439

Enrollment

Unknown

Registered

2019-11-13

Start date

2019-11-11

Completion date

Unknown

Last updated

2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea

Interventions

different concentrations of Botulinum Toxin A group:medical treatment

Eligibility

Sex/Gender

All

Age

16 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Conforms to the classification criteria of erythema telangiectasia in rose acne formulated by the National Rose Hemorrhoids Association Professional Committee; 2. Aged 20~50 years, gender is not limited.

Exclusion criteria

Exclusion criteria: 1. hormone-dependent dermatitis, contact dermatitis, acne, facial seborrheic dermatitis, skin infections, etc.; 2. allergic to any component of botulinum toxin type A; 3. lactating or pregnant women; 4. patients with severe systemic disease or a family history of skin malignancies.

Design outcomes

Primary

Measure	Time frame
PGA scores;	—

Countries

CHINA

Contacts

Public ContactYan Cao

The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University

czeycy2018@163.com+86 15961426236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026